Evaluation of rifaximin efficacy in complicated course of intestinal diverticular disease


Cite item

Full Text

Abstract

The results of the study that included 17 patients with diverticular disease (DD) complicated by diverticulitis, treated with rifaksimin in combination with symptomatic therapy are presented. Patients received antibiotic therapy in hospital within 10 days, and then patients were encouraged to continue to receive rifaksimin for 7 days within 3 months in the outpatient setting. Control group consisted of 16 patients with diverticulitis treated with ciprofloxacin for a similar regimen in conjunction with symptomatic therapy. Dynamic assessment results in 3 months later confirmed sufficient rifaksimin efficacy in patients with DD complicated by diverticulitis. Patients treated with rifaksimin had decrease frequency of abdominal pain on a background of moderate intestinal dysfunction. Rifaksimin therapy was accompanied by a reduction of inflammatory changes in the intestinal mucosa, colon microecology improvment. We observed positive dynamics in the number of mast cells as a marker of abatement of acute inflammation in the rifaksimin group. Thus, the study showed a high therapeutic efficacy of selective intestinal antibiotic in patients with diverticulitis.

References

  1. Ногаллер А.М., Юлдашев Н.Ю., Малыгин А.Г. Хронические колиты и дискинезии толстой кишки. Ташкент, 1989. 212 с.
  2. Воробьев Г.И., Панцырев Ю.М., Жученко А.П. и др. Острый дивертикулит сигмовидной кишки: клиника, диагностика и лечение // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007. № 4. С. 44-48.
  3. Шептулин А.А., Торрес Э.А. Современные возможности применения рифаксимина в гастроэнтерологии // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2008. № 5. С. 17-22.
  4. Adachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006;42(4):541-47.
  5. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005;5(1):19-30.
  6. Pistoia MA, Lombardi L, Rossi M, et al. Does rifaximin prevent complications of diverticular disease? A retrospective study. Eur Rev Med Pharmacol Sci 2004;8(6):283-87.
  7. Di Mario F, Aragona G, Leandro G, et al Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 2005;50:581-86.
  8. Frieri, G. Management of colonic diverticular disease. Bacterial flora in digestive disease. Focus on rifaximin / Eds. C. Scarpignato, A. Lanas. - Basel: Karger 2006:89-103.
  9. Gillis JC, Brogden <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Brogden%20RN%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus> RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49(3):467-84.
  10. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(Suppl. 1):36-66.
  11. Walsh LJ. Mast cells and oral inflammation. Crit Rev Oral Biol Med 2003;14(3):188-98.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies